Crackdown On Bad Regenerative Medicine Could Benefit Gene Therapy

US FDA to offer series of guidances on regenerative product development – and declares gene therapies eligible for RMAT – as enforcement against 'unscrupulous actors' continues.

Bad Apple
Will the bad apples make the public distrust the good ones?

More from Cell & Gene Therapies

More from Advanced Technologies